Pharvaris announced the appointment of David Nassif, J.D., as Chief Financial Officer, effective April 15, 2024. In this role, he will be responsible for refining and implementing Pharvaris? corporate financial strategy and activities including financial reporting and operations.

Mr. Nassif joins Pharvaris with more than 30 years of experience in financial management, strategic planning, mergers and acquisitions, investor relations, legal, and capital allocation, having held multiple executive financial management roles in development-stage, commercial-stage, public and private companies. Mr. Nassif serves as Chief Executive Officer, Chief Financial Officer, and Board Member at Sio Gene Therapies, where he raised $165 million in equity and was responsible for all finance, accounting, tax, treasury, legal, and SEC compliance and reporting activities. Sio is in dissolution and is returning significant capital to its stockholders.

Prior to joining Sio Gene, Mr. Nassif was Executive Vice President and Chief Financial Officer of SteadyMed Therapeutics, where he was instrumental in the company?s initial public offering in 2015 and its acquisition by United Therapeutics in August 2018. Over his career, Mr. Nassif has served as the Chief Financial Officer of Histogen, Zogenix, Amphastar Pharmaceuticals, and RealAge. Earlier, Mr. Nassif held various positions with Cypros Pharmaceuticals, where he was instrumental in leading its merger with Ribogene to form Questcor Pharmaceuticals.

He holds a B.S. in finance and management information systems with honors from the University of Virginia and a J.D. from the University of Virginia School of Law.